Lanean...
The Icelandic founder mutation BRCA2 999del5: analysis of expression
INTRODUCTION: A founder mutation in the BRCA2 gene (BRCA2 999del5) accounts for 7–8% of female breast cancers and for 40% of male breast cancers in Iceland. If expressed, the mutant gene would encode a protein consisting of the first 256 amino acids of the BRCA2 protein. The purpose of this study wa...
Gorde:
| Argitaratua izan da: | Breast Cancer Res |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2004
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC468616/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15217494/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/bcr785 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|